Patient Engagement Strategies to Transform Your Pharmacy LEARN MORE

EnlivenHealth® Empowers Pharmacies to Expand High-Value Clinical Services

Newly Launched Amplicare® Clinical Solution Uses Automation Designed to Enable Pharmacies to Provide and Efficiently Bill for Revenue-Generating Clinical Services Such as Vaccinations & Testing

RALEIGH, NC – July 28, 2022 – EnlivenHealth®, the retail pharmacy solutions division of Omnicell, Inc. (Nasdaq: OMCL), today announced the launch of Amplicare Clinical Solution, one of the industry’s most comprehensive suites of integrated technology solutions designed to transform the retail pharmacy. EnlivenHealth’s new automated technology suite should enable pharmacies to shift from focusing primarily on dispensing medications to providing, and efficiently billing for, a growing array of high-value clinical services, such as vaccinations, point-of-care testing, and health and wellness counseling.  

In the face of declining reimbursements and rising direct and indirect remuneration (DIR) fees, as well as the persistent challenges of inefficient pharmacy workflows, many retail pharmacies have realized they need to transform both their clinical practices and business operations to continue to thrive and grow. At the same time, the COVID-19 pandemic has accelerated the trend of pharmacies becoming an increasingly central, and uniquely trusted, player in community healthcare.1

EnlivenHealth’s new Amplicare Clinical Solution is intended to provide a fully integrated and automated suite of technology solutions that should enable pharmacies to meet these growing challenges and capitalize on emerging opportunities to provide highly accessible and trusted healthcare services. Amplicare Clinical Solution is expected to enable pharmacies to become true clinical services providers by automating the process of identifying patient opportunities, providing appropriate clinical care, and efficiently billing for those services, all in one integrated platform.

“Retail pharmacy now finds itself at the epicenter of community healthcare,” said Danny Sanchez, Senior Vice President and General Manager of EnlivenHealth. “Our new Amplicare Clinical Solution was purpose-built to help pharmacies strengthen and expand that growing role and was designed to keep patients healthy through medication adherence, while enabling revenue-generating clinical services. Our automated solutions suite should also help pharmacies reduce the administrative and operational burdens that keep pharmacists from practicing at the top of their license. We believe this really is a win-win for pharmacies, their patients, and community healthcare overall.”

Key clinical services enabled by the EnlivenHealth Amplicare Clinical Solution include:

  • Clinical Documentation & Task Management
  • Guided Care
  • Interoperability
  • Appointment Scheduling
  • Care Opportunities for Intervention (i.e., vaccinations for COVID-19, flu, etc.)
  • Medication Therapy Management (MTM)
  • Medical Billing
  • Promotional Opportunities

For more information, visit the Amplicare Clinical Solution web page or contact us to request a demo.

About EnlivenHealth®
EnlivenHealth builds advanced patient engagement, financial management and population health technology solutions that enable retail pharmacies and health plans to measurably improve the health of their patients and members, while ensuring the long-term health of their business. With the recent acquisitions of FDS Amplicare and MarkeTouch Media, EnlivenHealth now offers one of the industry’s most comprehensive suite of SaaS technology solutions that help retail pharmacies and health plans to transform and thrive in this new era of digital-driven healthcare. Currently, more than 50,000 retail pharmacies nationwide deploy EnlivenHealth/FDS Amplicare/MarkeTouch Media technology solutions. EnlivenHealth is a division of Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. To learn more, visit EnlivenHealth.co.

ENLIVENHEALTH and AMPLICARE are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

Forward-Looking Statements

Certain statements contained in this press release relate to the expected benefits and objectives of EnlivenHealth’s products and services, including Amplicare Clinical Solution (and any implied financial impact in connection with the foregoing). These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties some of which are beyond our control. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iv) unfavorable general economic and market conditions or reduction in demand for our solutions, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (vi) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and the legal, reputational and financial risks resulting from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (vii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, and (viii) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Contact:
Kelly Thotland
Marketing Manager, EnlivenHealth
kelly.thotland@omnicell.com


1. Pantasri, T. (2022). Expanded roles of community pharmacists in COVID-19: A scoping literature review. Journal of the American Pharmacists Association, 62(3), 649–657. https://doi.org/10.1016/j.japh.2021.12.013